Reduction of Tumour Oxygenation During and After Photodynamic Therapy in Vivo: Effects of Fluence Rate

Overview

Journal Br J Cancer

Specialty Oncology

Date 1998 Jul 4

PMID 9652753

Citations 50

Authors

T M Sitnik

J A Hampton

B W Henderson

Affiliations

Soon will be listed here.

Abstract

It has been proposed that the generation of O2 during photodynamic therapy (PDT) may lead to photochemical depletion of ambient tumour oxygen, thus causing acute hypoxia and limiting treatment effectiveness. We have studied the effects of fluence rate on pO2, in the murine RIF tumour during and after PDT using 5 mg kg(-1) Photofrin and fluence rates of 30, 75 or 150 mW cm(-2). Median pO2 before PDT ranged from 2.9 to 5.2 mmHg in three treatment groups. Within the first minute of illumination, median tumour pO2 decreased with all fluence rates to values between 0.7 and 1.1 mmHg. These effects were rapidly and completely reversible if illumination was interrupted. During prolonged illumination (20-50 J cm(-2)) pO2 recovered at the 30 mW cm(-2) fluence rate to a median value of 7.4 mmHg, but remained low at the 150 mW cm(-2) fluence rate (median pO2 1.7 mmHg). Fluence rate effects were not found after PDT, and at both 30 and 150 mW cm(-2) median tumour pO2 fell from control levels to 1.0-1.8 mmHg within 1-3 h after treatment conclusion. PDT with 100 J cm(-2) at 30 mW cm(-2) caused significantly (P = 0.0004) longer median tumour regrowth times than PDT at 150 mW cm(-2), indicating that lower fluence rate can improve PDT response. Vascular perfusion studies uncovered significant fluence rate-dependent differences in the responses of the normal and tumour vasculature. These data establish a direct relationship between tumour pO2, the fluence rate applied during PDT and treatment outcome. The findings are of immediate clinical relevance.

Citing Articles

Systematic review: Mechanisms of photoactive nanocarriers for imaging and therapy including controlled drug delivery.

Zhang Y, Qiu Y, Karimi A, Smith B Eur J Nucl Med Mol Imaging. 2024; 52(4):1576-1595.

PMID: 39722062 PMC: 11849580. DOI: 10.1007/s00259-024-07014-z.

Devices and Methods for Dosimetry of Personalized Photodynamic Therapy of Tumors: A Review on Recent Trends.

Alekseeva P, Makarov V, Efendiev K, Shiryaev A, Reshetov I, Loschenov V Cancers (Basel). 2024; 16(13).

PMID: 39001546 PMC: 11240380. DOI: 10.3390/cancers16132484.

Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures.

Krupka-Olek M, Bozek A, Czuba Z, Klosek M, Cieslar G, Kawczyk-Krupka A Pharmaceutics. 2024; 16(6).

PMID: 38931819 PMC: 11207107. DOI: 10.3390/pharmaceutics16060696.

Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer.

Baydoun M, Boidin L, Leroux B, Vignion-Dewalle A, Quilbe A, Grolez G Int J Mol Sci. 2023; 24(14).

PMID: 37511049 PMC: 10378870. DOI: 10.3390/ijms241411288.

Spotlight on Photoactivatable Liposomes beyond Drug Delivery: An Enabler of Multitargeting of Molecular Pathways.

Saad M, Hasan T Bioconjug Chem. 2022; 33(11):2041-2064.

PMID: 36197738 PMC: 10351218. DOI: 10.1021/acs.bioconjchem.2c00376.

References

Nichols M, Foster T . Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumour spheroids. Phys Med Biol. 1994; 39(12):2161-81. DOI: 10.1088/0031-9155/39/12/003. View

Bellnier D, Greco W, Parsons J, Oseroff A, Kuebler A, Dougherty T . An assay for the quantitation of Photofrin in tissues and fluids. Photochem Photobiol. 1997; 66(2):237-44. DOI: 10.1111/j.1751-1097.1997.tb08649.x. View

Twentyman P, Brown J, Gray J, Franko A, Scoles M, Kallman R . A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980; 64(3):595-604. View

Gomer C, Razum N . Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions. Photochem Photobiol. 1984; 40(4):435-9. DOI: 10.1111/j.1751-1097.1984.tb04614.x. View

Moan J, Sommer S . Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res. 1985; 45(4):1608-10. View

Henderson B, Fingar V . Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 1987; 47(12):3110-4. View

Rofstad E, Fenton B, Sutherland R . Intracapillary HbO2 saturations in murine tumours and human tumour xenografts measured by cryospectrophotometry: relationship to tumour volume, tumour pH and fraction of radiobiologically hypoxic cells. Br J Cancer. 1988; 57(5):494-502. PMC: 2246390. DOI: 10.1038/bjc.1988.113. View

Henderson B, Fingar V . Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol. 1989; 49(3):299-304. DOI: 10.1111/j.1751-1097.1989.tb04110.x. View

Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

10.

Tromberg B, Orenstein A, Kimel S, Barker S, Hyatt J, Nelson J . In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol. 1990; 52(2):375-85. DOI: 10.1111/j.1751-1097.1990.tb04193.x. View

11.

Gibson S, VanDerMeid K, Murant R, Raubertas R, HILF R . Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res. 1990; 50(22):7236-41. View

12.

Foster T, Murant R, Bryant R, Knox R, Gibson S, HILF R . Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 1991; 126(3):296-303. DOI: 10.2307/3577919. View

13.

Vaupel P, Schlenger K, Knoop C, Hockel M . Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991; 51(12):3316-22. View

14.

Lyng H, Skretting A, Rofstad E . Blood flow in six human melanoma xenograft lines with different growth characteristics. Cancer Res. 1992; 52(3):584-92. View

15.

Henderson B, Dougherty T . How does photodynamic therapy work?. Photochem Photobiol. 1992; 55(1):145-57. DOI: 10.1111/j.1751-1097.1992.tb04222.x. View

16.

Fingar V, Wieman T, Wiehle S, Cerrito P . The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 1992; 52(18):4914-21. View

17.

Fingar V, Wieman T, Park Y, Henderson B . Implications of a pre-existing tumor hypoxic fraction on photodynamic therapy. J Surg Res. 1992; 53(5):524-8. DOI: 10.1016/0022-4804(92)90101-5. View

18.

Foster T, Hartley D, Nichols M, HILF R . Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res. 1993; 53(6):1249-54. View

19.

Fenton B, Way B . Vascular morphometry of KHT and RIF-1 murine sarcomas. Radiother Oncol. 1993; 28(1):57-62. DOI: 10.1016/0167-8140(93)90186-c. View

20.

STONE H, Brown J, Phillips T, Sutherland R . Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res. 1993; 136(3):422-34. View